Feature|Articles|November 19, 2026

Keeping Patients in the Loop as AI Enters Clinical Research: Q&A with Stacy Hurt

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The narrative forming around AI in the pharma and biotech industries is less focused on if the technology should be used, it’s when it should be used. The powerful technology has the capability to be implemented in a variety of workflows, but that doesn’t always mean that it’s being used in a way that gets the best results.

Pharmaceutical Executive spoke with Stacy Hurt, chief patient officer at Parexel, about her views on AI-usage in clinical research. This is an area where she sees tremendous potential for the advanced tech, but she also sees a need to ensure that patients are being the given to provide input in the process as well.

When it’s not used properly, AI may create situations where patients are facing improperly designed research scenarios or struggling with poor communication. However, she also argues that when properly implemented, the AI can allow for a greater level of understanding of the patients’ viewpoints and allow not just for easier communication, but deeper communication as well.

Click here for the video version of this interview!

Pharmaceutical Executive: Where can AI strengthen clinical research?
Stacy Hurt: I definitely think that AI can strengthen clinical research by making trials smarter, better, and faster — and the way that translates to patients is bringing treatments, cures, and improved quality of life to them more quickly. Every minute matters to patients, especially when you’re talking about advanced cancer or rare disease. Those minutes translate to moments, and every moment matters. So any way that AI can expedite that is important and meaningful to patients.

Patient input is important from the very beginning, and there’s no replacement for lived patient experience. I said the other day in one of my posts that until AI sits in a chemotherapy chair with chemotherapy running through its veins 55 times — experiencing nausea, fatigue, constipation, diarrhea — there’s no way it can substitute for what patients go through on a daily basis. So AI is complementary to patient experience. Patients know that AI is based on the prompts you give it; it trains on what prompts you give it. So it takes patients asking the right questions from their lived experience to train that AI and work in tandem with patients to improve clinical research for optimal results.

PE: When should patient input be collected in the clinical research process?
Hurt: Patient input should be considered from the very beginning — from the earliest possible stages. Sometimes we hear pushback from sponsors in phase one clinical trials: “That’s not going to be meaningful until we get further along.” I push back and say this is especially where patient input is important, because it can improve the process from the start. A couple extra months of patient input at the beginning can translate to saved years at the end. We know that an amendment in a phase three clinical trial costs an average of $535,000. So having that patient input at the beginning — being proactive, mitigating risk, and heading off those amendments — is tremendously cost-effective for sponsors and meaningful to patients.

PE: How does patients' AI usage impact how sponsors communicate with them?
Hurt: We know that right now, on average, about 60% of Americans are using AI-related tools such as ChatGPT for their own health benefits. In my advocacy work, I actually encourage patients to take their diagnosis and plan of care and put it into ChatGPT — but I also encourage them to bring that to their physician’s office and work with their healthcare professional team as a collaboration for the best possible treatment plan. AI is alive and well in patients’ hands, and I think that’s what we’re going for: empowering patients. We want patients using these tools to improve their care, to have an empowered dialogue with their healthcare professional team, and to have the latest research at their fingertips.

PE: How do small protocol decisions become enrollment or retention barriers?
Hurt: In my 30 years in healthcare, I don’t think I’ve ever encountered a small protocol decision — because every protocol decision matters to patients, no matter how small or large the trial. When we receive a proposal at Par Excel and review a protocol, my role as chief patient officer is to bring an authentic patient voice to it: patient eyes looking at that protocol through the lens of lived experience with that disease. We don’t have to put ourselves in patients’ shoes, because we are bringing patients’ shoes to the protocol — to identify areas of burden or areas of risk.

Biopsies, for example, are tremendously burdensome to patients. I had one 10 years ago — a needle this long going into my liver — and I remember it every single day. So when we review protocols that call for multiple biopsies, we have patients with lived experience look at that and ask: how can we minimize that burden? Maybe a liquid biopsy can return the same data and be far less invasive. Those kinds of decisions can only be identified by patients who are living with that disease and would have to endure that burden — and who need to stay in the trial.


Related to this article